Pediapharm MK 17M Symbol: PDP / WKN: A14Q5H
Seite 5 von 5 Neuester Beitrag: 24.04.21 23:28 | ||||
| Eröffnet am: | 05.10.15 18:22 | von: Drölö | Anzahl Beiträge: | 120 |
| Neuester Beitrag: | 24.04.21 23:28 | von: Antjekcbaa | Leser gesamt: | 33.363 |
| Forum: | Hot-Stocks | Leser heute: | 8 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | 4 | > | ||||
https://www.google.com/finance?cid=452434813362000
Feb 23, 2017
Q3 2017 Pediapharm Inc Earnings Release (Estimated)
Nov 28, 2016
Q2 2017 Pediapharm Inc Earnings Release
Steht ja auch "Extimated"
Aber: Hier noch ein tolles Video:
https://www.youtube.com/watch?v=fDdTa9roG8A
Schönes Wochenende noch!
Gruß und schönes Wochenende!
Gerade rumgestöbert und dieses Interview entdeckt von letzter Woche:
http://biotech-tv.com/?v=297513
Pediapahrm hat gerade ein PP zu 0,34 CAD je Aktie in höhe von 5.000.000 $ bekannt gegeben.
PEDIAPHARM ARRANGES PRIVATE PLACEMENT OF UNITS FOR $5,000,000
Pediapharm Inc. has agreed to a non-brokered private placement of 14,705,883 units of the company at a price of 34 cents per unit, for gross proceeds of $5-million...
The net proceeds of this Offering will be used to secure new business opportunities...
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aPDP-2471318
Da eigentlich genug Cash vorhanden ist, ca 5.000.000 Stand 31.03.2016 laut Sedar ( http://www.sedar.com/...anyDocuments.do?lang=FR&issuerNo=00035274 ), bin ich auf neue Produktaquisitionen nach dem closing Date (23.05.2017) gespannt.
Optionen
http://www.stockwatch.com/News/Item.aspx?bid=Z-C:PDP-2472693
Optionen
Und es geht weiter voran! 
In the three-month period ended June 30, 2017, the Company achieved record quarterly revenue of $2,465,550 (three-month period ended June 30, 2016 - $893,161), representing an increase of 176%
24% increase from NYDA;
12% increase from Naproxen Suspension
Revenue from Rupall(TM), launched in late January 2017, which has significantly exceeded Management's original estimate by more than 40%. Management now estimates the peak sales of Rupall(TM) will reach $10-12 million in 5 to 7 years
Revenue from Relaxa(TM) which was in line with Management's estimate of approximately $3 million on an annual basis
In June 2017, the Company closed a non-brokered private placement of $5,000,000 with a company owned by Gerard Leduc, a globally known pharmaceutical executive.
Net working capital of over $7.3M
The Cuvposa dossier is progressing as expected and so, the Company still expects a decision from Health Canada before the end of October 2017
zurücklehnen und zusehen. 
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aPDP-2497906
Optionen
...at the creation of Aventis, he was appointed vice-president, commercial affairs. After a merger with Sanofi, he held several commercial executive positions in Canada, his last Canadian position being vice-presidentm diabetes and specialized care patient centred unit. His last assignment with Sanofi before retirement was vice-president, global portfolio management and strategic development, based in Prague, Czech Republic, in the global generics division....
http://www.stockwatch.com/News/Item.aspx?bid=Z-C:PDP-2508925
Na da ist ein fähiger Mann an Bord gekommen.
Folgende Positionen hat Herr Gravel bei Sanofi seit dem Jahr 2000 durchlaufen:
- VP Commercial Affairs
- VP Business Support and Market Access
- VP Planning & Strategic Development
- VP Field & Operations and Canada Consumer Healthcare
- Vice President Portfolio Management & Business Development, Global Generic Division
Optionen
Optionen
http://www.reuters.com/article/...-approval-for-cuvposa-idUSFWN1N70WA
Optionen
Und wieder ein schöner Sprung 
In the three-month period ended Sept. 30, 2017, the company achieved record quarterly revenue of $3,083,397 (three-month period ended Sept. 30, 2016 -- $1,882,147), representing an increase of 64 per cent including:
- 3-per-cent increase from NYDA;
- 32-per-cent increase from naproxen suspension;
- Revenue from Relaxa, which was in line with management's estimate of approximately $3.1-million on an annual basis;
- Revenue from Rupall, launched in late January, 2017, which has significantly exceeded management's original estimate by 60 per cent;
- Revenue from Otixal, launched in May, 2017, which were in line with management's estimate.
In the three-month period ended Sept. 30, 2017, the company achieved positive adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of $87,578 versus ($328,282) in the three-month period ended Sept. 30, 2016. This is the company's first quarter with positive adjusted EBITDA.
Schaue gespannt auf die nächsten Monate und bleibe Long. Werde auch noch nachlegen so lange der Kurs um oder unter die 0,3 CAD ist.
Haben ja eine weitere Zulassung enthalten und noch ne Menge Wachstum vorraus
http://www.stockwatch.com/News/Item.aspx?bid=Z-C:PDP-2536818
Optionen
https://www.stockwatch.com/News/Item.aspx?bid=Z-C:PDP-2656333